PharmaCyte Biotech (PMCB) Income from Continuing Operations (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Income from Continuing Operations of 21800362.0 for Q2 2026, down 35.97% year-over-year from 34044886.19 in Q2 2025, and down 1055.03% quarter-over-quarter from 1887434.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Income from Continuing Operations (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Income from Continuing Operations for 17 consecutive years, with 21800362.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 35.97% year-over-year to 21800362.0; the TTM figure through Apr 2026 stood at 25487972.0 (down 40.17% YoY), while the FY2026 annual figure was 21408795.0, up 13.05% from the prior year.
- Income from Continuing Operations declined to 21800362.0 in Q2 2026 per PMCB's latest filing, from 1887434.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 180346.0 in Q2 2023 and bottomed at 21800362.0 in Q2 2026.
- Historically, Income from Continuing Operations has averaged 3930077.83 across 5 years, with a median of 1078474.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations soared 87.31% — and 2024, when it sank 9666.14%.
- PharmaCyte Biotech's Income from Continuing Operations stood at 1881765.0 in 2022, then jumped by 72.61% to 515339.0 in 2023, then tumbled by 40.39% to 723498.0 in 2024, then plunged by 61.67% to 1169664.0 in 2025, then sank by 1763.81% to 21800362.0 in 2026.
- Business Quant data shows PMCB's Income from Continuing Operations at 21800362.0 in Q2 2026, 1887434.0 in Q1 2026, and 1169664.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | -2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -21.80 Mn |
| Jan 31, 2026 | -1.89 Mn |
| Oct 31, 2025 | -1.17 Mn |
| Jul 31, 2025 | -630,512.00 |
| Apr 30, 2025 | -16.03 Mn |
| Jan 31, 2025 | -704,560.00 |
| Oct 31, 2024 | -723,498.00 |
| Jul 31, 2024 | -721,455.00 |
| Apr 30, 2024 | -17.61 Mn |
| Jan 31, 2024 | -987,284.00 |
| Oct 31, 2023 | -515,339.00 |
| Jul 31, 2023 | -1.20 Mn |
| Apr 30, 2023 | -180,346.00 |
| Jan 31, 2023 | -912,130.00 |
| Oct 31, 2022 | -1.88 Mn |
| Jul 31, 2022 | -1.55 Mn |
| Apr 30, 2022 | -1.42 Mn |
| Jan 31, 2022 | -814,913.00 |
| Oct 31, 2021 | -986,104.00 |
| Jul 31, 2021 | -1.02 Mn |